共 50 条
- [1] Efficacy and Safety of Sarilumab Versus Adalimumab in a Phase 3, Randomized, Double-Blind, Monotherapy Study in Patients with Active Rheumatoid Arthritis with Intolerance or Inadequate Response to MethotrexateARTHRITIS & RHEUMATOLOGY, 2016, 68Burmester, GerdLin, YongPatel, Rahulvan Adelsberg, JanetMangan, Erinvan Hoogstraten, HubertBauer, DeborahIgnacio Vargas, JuanLee, Eun Bong
- [2] Upadacitinib As Monotherapy: A Phase 3 Randomized Controlled Double-Blind Study in Patients with Active Rheumatoid Arthritis and Inadequate Response to MethotrexateARTHRITIS & RHEUMATOLOGY, 2018, 70Smolen, Josef S.Cohen, StanleyEmery, PaulRigby, William F. C.Tanaka, YoshiyaZhang, YingFriedman, AlanOthman, Ahmed A.Camp, Heidi S.Pangan, Aileen L.
- [3] UPADACITINIB AS MONOTHERAPY: A PHASE 3 RANDOMIZED CONTROLLED DOUBLE-BLIND STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATEJCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S52 - S52Smolen, J. S.Cohen, S.Emery, P.Rigby, W.Tanaka, Y.Zhang, Y.Friedman, A.Othman, A. A.Camp, H. S.Pangan, A. L.
- [4] A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib to Placebo and to Adalimumab, in Patients with Active Rheumatoid Arthritis with Inadequate Response to MethotrexateARTHRITIS & RHEUMATOLOGY, 2018, 70Fleischmann, RoyPangan, Aileen L.Mysler, EduardoBessette, LouisPeterfy, CharlesDurez, PatrickOstor, AndrewLi, YihanZhou, YijieOthman, Ahmed A.Song, In-HoGenovese, Mark C.
- [5] EFFICACY AND SAFETY OF SARILUMAB MONOTHERAPY VERSUS ADALIMUMAB MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS IN THE PHASE 3 MONARCH STUDY, INCLUDING SUBPOPULATIONSANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 849 - 849Burmester, G. R.Lin, Y.Mangan, E. K.van Hoogstraten, H.Kimura, T.Vargas, J. I.Lee, E. B.
- [6] UPADACITINIB AS MONOTHERAPY: A PHASE 3 RANDOMISED CONTROLLED DOUBLE-BLIND STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATERHEUMATOLOGY, 2019, 58Smolen, J. S.Cohen, S.Emery, P.Rigby, W.Tanaka, Y.Zhang, Y.Friedman, A.Othman, A. A.Camp, H. S.Pangan, A. L.
- [7] UPADACITINIB AS MONOTHERAPY: A PHASE 3 RANDOMISED CONTROLLED DOUBLE-BLIND STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATEANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 67 - 68Smolen, J.Cohen, S.Emery, P.Rigby, W.Tanaka, Y.Zhang, Y.Friedman, A.Othman, A.Camp, H.Pangan, A.
- [8] Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trialANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (05) : 840 - 847Burmester, Gerd R.Lin, YongPatel, Rahulvan Adelsberg, JanetMangan, Erin K.Graham, Neil M. H.van Hoogstraten, HubertBauer, DeborahIgnacio Vargas, JuanLee, Eun Bong
- [9] Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled TrialARTHRITIS & RHEUMATOLOGY, 2019, 71 (11) : 1788 - 1800Fleischmann, RoyPangan, Aileen L.Song, In-HoMysler, EduardoBessette, LouisPeterfy, CharlesDurez, PatrickOstor, AndrewJLi, YihanZhou, YijieOthman, Ahmed A.Genovese, Mark C.
- [10] A Phase IIb, Randomized, Double-blind Study in Patients with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Patients with an Inadequate Response to MethotrexateARTHRITIS & RHEUMATOLOGY, 2020, 72Peterfy, CharlesBuch, MayaChoy, ErnestSchett, GeorgParsons-Rich, DanaPatel, AnandZima, YuliaLe Bolay, ClaireGenovese, Mark